share_log

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Jasper Therapeutics將參加即將舉行的投資者會議
Jasper Therapeutics ·  11/13 13:00
PDF Version
PDF版本

REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences:

加利福尼亞州雷德伍德城,2024年11月13日(GLOBE NEWSWIRE) -- 珍珀治療公司(Nasdaq: JSPR) (Jasper),一家臨床階段的生物技術公司,專注於開發briquilimab,一種針對c-Kit (CD117)的新型抗體療法以應對血液電芯驅動的疾病,如慢性特發性蕁麻疹(CSU),慢性誘發性蕁麻疹(CIndU)和哮喘,今日宣佈將參加以下投資者會議:

Stifel 2024 Healthcare Conference
Conference Dates: November 18 – 19, 2024
Presentation Date: Monday, November 18, 2024, 9:45 a.m. ET
Presentation Format: Fireside Chat

2024年史蒂夫爾醫療保健大會
會議日期:2024年11月18日至19日
演講日期:2024年11月18日,東部時間上午9:45
演講形式:爐邊談話

Jefferies London Healthcare Conference 2024
Conference Dates: November 19-21, 2024

2024年Jefferies倫敦醫療保健大會
會議日期:2024年11月19日至21日

7th Annual Evercore ISI HealthCONx Conference
Conference Dates: December 3-5, 2024
Presentation Date: Tuesday, December 3, 2024, 3:25 p.m. ET
Presentation Format: Fireside Chat

第7屆Evercore ISI HealthCONx會議
會議日期:2024年12月3日至5日
演示日期:2024年12月3日星期二,東部時間下午3:25
演講形式:爐邊談話

Live webcasts of the presentations will be available on the Events & News – Events page of Jasper's Investor Relations website. An archived replay of each presentation will be available on Jasper's website for 30 days following the applicable live broadcast.

演示的實時網絡直播將在Jasper投資者關係網站的活動與資訊 – 事件頁面上提供。每場演示的錄播將於直播結束後的30天內在Jasper的網站上提供。

About Jasper

關於Jasper

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and asthma and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in more than 160 dosed participants and healthy volunteers, with clinical outcomes in CIndU and as a conditioning agent in SCID, acute myeloid leukemia, myelodysplastic syndromes, FA, and SCD. For more information, please visit us at .

Jasper是一家臨床階段的生物技術公司,正在開發briquilimab,這是一種針對c-Kit (CD117)的單克隆抗體,用於治療慢性肥大細胞和幹細胞疾病,如慢性蕁麻疹和哮喘,同時也作爲用於治療罕見疾病如鐮狀細胞病(SCD)、範可尼貧血(FA)與重症聯合免疫缺陷(SCID)的幹細胞移植的準備劑。截至目前,briquilimab在超過160名接受治療的參與者和健康志願者中展示了有效性和安全性,在CIndU及作爲SCID、急性髓性白血病、骨髓增生異常綜合症、FA和SCD的準備劑的臨床結果方面表現良好。如需更多信息,請訪問我們的網站。

Forward-Looking Statements

前瞻性聲明

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Jasper's presentations at the Stifel 2024 Healthcare Conference, the Jefferies 2024 London Healthcare Conference 2024 and the 7th Annual Evercore ISI HealthCONx Conference, and briquilimab's potential to address mast cell driven diseases such as CSU, CIndU and asthma. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

本新聞稿中包含的某些陳述不是歷史事實,而是根據1995年美國私人證券訴訟改革法案的安全港規定而作出的前瞻性聲明。前瞻性聲明有時伴隨着如「相信」、「可能」、「將」、「估計」、「繼續」、「預期」、「打算」、「期待」、「應該」、「會」、「計劃」、「預測」、「潛在」、「似乎」、「尋求」、「未來」、「展望」和類似的表達,預測或指示未來事件或趨勢,或不是歷史事項的陳述。這些前瞻性聲明包括但不限於關於Jasper在Stifel 2024年醫療會議、Jefferies 2024年倫敦醫療會議以及第七屆evercore ISI HealthCONx會議的演講,以及briquilimab在治療如CSU、CIndU和哮喘等肥大細胞驅動疾病方面的潛力。這些聲明基於各種假設,無論是否在本新聞稿中明確提及,並基於Jasper的當前預期,並不代表實際表現的預測。這些前瞻性聲明僅供說明用途,不應被投資者視作保證、保證、預測或確定的事實或概率聲明。許多實際事件和情況超出Jasper的控制範圍。這些前瞻性聲明面臨許多風險和不確定性,包括一般經濟、政治和商業條件;Jasper開發的潛在產品候選物可能無法按預期時間進展臨床開發或獲得所需的監管審批的風險;臨床試驗可能無法確認本新聞稿中描述或假設的任何安全性、效力或其他產品特性;先前的測試、研究和試驗結果可能無法在持續或未來的研究和試驗中複製的風險;Jasper可能無法成功市場推廣或獲得其產品候選物的市場接受度的風險;先前研究結果可能無法複製的風險;Jasper的產品候選物可能對患者無益或無法成功商業化的風險;患者嘗試新療法的意願及醫生處方這些療法的意願;競爭對Jasper業務的影響;第三方對Jasper依賴的實驗室、臨床開發、製造及其他關鍵服務未能令人滿意履行的風險;Jasper的業務、運營、臨床發展計劃和時間表以及供應鏈可能受到健康流行病影響的不利影響的風險;Jasper將無法獲得和維持其研究產品的足夠知識產權保護,或會侵犯他人的知識產權保護的風險;以及其他在Jasper向證券交易委員會提交文件時不時指出的風險和不確定性,包括截至2023年12月31日的年度報告10-k表格及其隨後10-Q表格的季度報告。如果其中任何風險實現或Jasper的假設被證明不正確,實際結果可能與這些前瞻性聲明所暗示的結果大相徑庭。雖然Jasper可能選擇在未來的某個時刻更新前瞻性聲明,但Jasper特此明確表示對此沒有任何義務。這些前瞻性聲明不應被依賴爲Jasper對本新聞稿日期之後任何日期的評估。因此,不應對前瞻性聲明寄予過度依賴。

Contacts:

聯繫人:

Joyce Allaire (investors)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com

Joyce Allaire(投資人)
LifeSci顧問
617-435-6602
jallaire@lifesciadvisors.com

Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertherapeutics.com

Alex Gray(投資人)
Jasper治療
650-549-1454
agray@jaspertherapeutics.com

Lauren Walker (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com

Lauren Walker(媒體)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論